Prevalence and Associated Factors of Portopulmonary Hypertension in Patients with Portal Hypertension: A Case-Control Study
Table 1
Analysis of demographic situation of the POPH group and non-POPH group.
Variables
POPH ()
Non-POPH ()
Age (years)
-1.541
0.125
Gender (%)
Male
12 (42.9)
110 (68.7)
7.017
<0.01
Female
16 (57.1)
50 (31.3)
Etiology (%)
HBV
10 (35.7)
71 (44.4)
0.729
0.393
HCV
2 (7.1)
21 (13.1)
—
0.537
Alcohol
9 (32.1)
37 (23.1)
1.049
0.306
Drug
1 (3.6)
6 (3.8)
—
1.00
Autoimmune
3 (10.7)
14 (8.8)
—
0.723
Liver cancer (%)
Yes
4 (14.3)
51 (31.9)
3.562
0.059
No
24 (85.7)
109 (68.1)
Hypertension (%)
Yes
5 (17.9)
22 (13.7)
—
0.563
No
23 (82.1)
138 (86.3)
Diabetes (%)
Yes
3 (10.7)
30 (18.8)
—
0.422
No
25 (89.3)
130 (81.3)
Splenectomy (%)
Yes
6 (21.4)
21 (13.1)
—
0. 249
No
22 (78.6)
139 (86.9)
Portal vein thrombosis (%)
Yes
4 (14.3)
21 (13.1)
—
0.771
No
24 (85.7)
139 (86.9)
The diagnosis of portal hypertension in this study is based on the 2016 Practice Guidance by the AASLD on Portal Hypertensive Bleeding in Cirrhosis [9]. All patients had manifestations of liver cirrhosis and portal hypertension confirmed by abdominal imaging (ultrasound, CT, or MRI), and most patients had complications of portal hypertension at the time of admission, such as portal hypertensive bleeding and ascites.
